Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 20 2017 - 5:22PM
Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company
engaged in the research and development of new medicines to treat
serious infections, with a focus on the pleuromutilin class of
antibiotics, today announced that Chief Executive Officer Colin
Broom, M.D., will provide a company overview, including the
previously released lefamulin evaluation against pneumonia (LEAP 1)
Phase 3 trial topline results, and business update at the Cantor
Fitzgerald Global Healthcare Conference on Monday, September 25,
2017 at 2:25 p.m. ET. The conference is being held at the
InterContinental New York Barclay Hotel in New York, NY.
The presentation will be webcast live and may be accessed by
visiting the “Investors” section of the company’s website under the
“Events and Presentations” tab at www.nabriva.com. A replay of the
webcast will be available for 90 days.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in
the research and development of new medicines to treat serious
bacterial infections, with a focus on the pleuromutilin class of
antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise
has enabled targeted discovery of novel pleuromutilins, including
both intravenous and oral formulations. Nabriva Therapeutics’ lead
product candidate, lefamulin, is a novel semi-synthetic
pleuromutilin antibiotic with the potential to be the
first-in-class available for systemic administration in humans. The
company believes that lefamulin is the first antibiotic with a
novel mechanism of action to have reached late-stage clinical
development in more than a decade. Nabriva has announced positive
topline data for lefamulin from the first of its two global,
registrational Phase 3 clinical trials evaluating lefamulin in
patients with moderate to severe community-acquired bacterial
pneumonia (CABP). Nabriva Therapeutics believes lefamulin is
well-positioned for use as a first-line empiric monotherapy for the
treatment of moderate to severe CABP due to its novel mechanism of
action, targeted spectrum of activity, resistance profile,
achievement of substantial drug concentration in lung tissue and
fluid, oral and IV formulations and a favorable tolerability
profile. Nabriva Therapeutics is exploring potential further
development of lefamulin for additional indications, including the
treatment of acute bacterial skin and skin structure infections
(ABSSSI), and is developing a formulation of lefamulin appropriate
for pediatric use.
Nabriva Therapeutics owns exclusive, worldwide rights to
lefamulin, which is protected by composition of matter patents
issued in the U.S., Europe and Japan.
Forward Looking Statements
Any statements in this press release about
future expectations, plans and prospects for Nabriva, including but
not limited to statements about the development of Nabriva’s
product candidates, such as plans for the design, conduct and
timelines of Nabriva’s ongoing Phase 3 clinical trial of lefamulin
for CABP, the clinical utility of lefamulin for CABP and Nabriva’s
plans for filing of regulatory approvals and efforts to bring
lefamulin to market, the development of lefamulin for additional
indications, the development of additional formulations of
lefamulin, plans to pursue research and development of other
product candidates, the sufficiency of Nabriva’s existing cash
resources and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “likely,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation and conduct of clinical
trials, availability and timing of data from clinical trials,
whether results of early clinical trials or trials in different
disease indications will be indicative of the results of ongoing or
future trials, whether results of Nabriva’s first Phase 3 clinical
trial of lefamulin will be indicative of the results for its second
Phase 3 clinical trial of lefamulin, uncertainties associated with
regulatory review of clinical trials and applications for marketing
approvals, the availability or commercial potential of product
candidates including lefamulin for use as a first-line empiric
monotherapy for the treatment of moderate to severe CABP, the
sufficiency of cash resources and need for additional financing and
such other important factors as are set forth under the caption
“Risk Factors” in Nabriva’s annual and quarterly reports on file
with the U.S. Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Nabriva’s views as of the date of this release. Nabriva anticipates
that subsequent events and developments will cause its views to
change. However, while Nabriva may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Nabriva’s views as of any date subsequent to the date
of this release.
CONTACT:
INVESTOR RELATIONSDave GarrettNabriva Therapeutics
plcdavid.garrett@nabriva.com610-816-6657
MEDIAKatie EnglemanPure
Communicationskengleman@purecommunications.com910-509-3977
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Sep 2023 to Sep 2024